Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 14

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 14
---
 EBITDA 1 Please refer to 2025 Guidance (including the impact of IRA) on page 38 of the Capital Markets Day Presentation (27 Feb 2025).

- 18 - Q1 2025 Results Final Remarks Nacho Abia Chief Executive Officer (CEO)

- 19 - Q1 2025 Results Grifols remains focused on the execution of the strategic plan Q1’25: Ahead of Plan FY’25 Guidance 1 : Well on - track Committed to improving FCF generation and continued deleveraging Operational excellence and R&D pipeline execution to deliver further margin expansion Corporate simplification and portfolio optimization continues as planned Well positioned to navigate highly dynamic markets 01 02 03 04 05 06 Grifols Continues to Deliver Strong Results Driven by Strategic Plan Execution Business Performance Financials Final Remarks Annex 1 See slide 38 of the Capital Markets Day presentation

- 20 - Q1 2025 Results ANNEX

- 21 - Q1 2025 Results Revenue | Q1 2025 Q1 2025 Q1 2024 In thousands of euros Reported At cc* Revenue by Business Unit 1,785,809 1,625,705 9.8% 7.4% Biopharma 1,521,160 1,394,703 9.1% 6.6% Diagnostic 170,043 158,283 7.4% 5.2% Bio Supplies 32,557 27,013 20.5% 15.9% Others & intersegments 62,050 45,707 35.8% 34.0% Revenue by Country 1,785,809 1,625,705 9.8% 7.4% US + CANADA 1,025,190 925,326 10.8% 6.4% EU 390,275 331,427 17.8% 17.6% ROW 370,344 368,952 0.4% 0.8% * Constant currency (cc) excludes exchange rate fluctuations over the period. Grifols Grifols % vs PY Business Performance Financials Final Remarks Annex

- 22 - Q1 2025 Results P&L | Q1 2025 Business Performance Financials Final Remarks Annex In thousands of euros Reported One-offs Reported excl. One-offs Reported One-offs Reported excl. One-offs Reported Reported